Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
NERASS Najaarscongres: 'What’s new in CRPS & OA'
jan 2019 | Artrose